INTRODUCTION
============

Medication use increases with age in terms of frequency (prevalence of use in the population) and intensity (amount of medications used)[@B1]. This is due to the greater presence of diseases and chronic conditions, whose treatment has an important support in pharmacotherapy[@B2]. This greater use results in a complex therapeutic regimen, intensifies adverse drug reactions (especially in aged organisms), and increases costs[@B3], which may lead to non-adherence to prescribed treatment.

Underuse of medications is a type of non-adherence to drug treatment. There are different types of underuse, such as not acquiring all prescribed medications, reducing the number of tablets, or changing the dose used[@B4]. Underuse may be the last obstacle to the access to an effective therapy, when other barriers (inaccessibility to service and inadequate prescriptions) are overcome. It compromises the effectiveness of treatment, which increases health risks and, consequently, overload health services[@B5]. The increase in the price of medications, the different mechanisms that cover their costs (public or private), and the user's purchasing power are the main reasons for cost-related underuse of medications, but they are not their only determinants[@B4].

International studies have reported that, in addition to contextual financial pressures and the organization of health services, other factors influence the underuse of medications, such as sociodemographic characteristics (sex, age, education level) and health conditions (self-rated health and chronic diseases)^6--11^.

In Brazil, two studies have investigated cost-related underuse of medications among older persons living in the Metropolitan Region of Belo Horizonte[@B12] ^,^ [@B13], but no previous study has investigated this issue in a nationally based sample of older Brazilians. Thus, this study aimed to investigate the prevalence and individual factors associated with cost-related underuse of medications in a nationally representative sample of the Brazilian population aged 50 years and over.

METHODS
=======

Study population
----------------

This cross-sectional study used baseline data from the Brazilian Longitudinal Study of Aging (ELSI-Brazil), which is a nationwide population-based study on the living, health, and well-being conditions of the Brazilian population aged 50 years and over. The baseline survey was conducted in 2015 and 2016. The sampling design was based on selection stages, which combined municipality, census tract, and household. Municipalities were allocated in four strata according to their population size: (1) ≤ 26,700 inhabitants, (2) 26,701--135,000 inhabitants, (3) 135,001--750,000 inhabitants, and (4) \> 750000 inhabitants. In the first three strata, sampling was carried out in three stages (municipalities, census tract, and household); in the fourth stratum, all municipalities were selected and the sampling was carried out in two stages (census tract and household). All persons aged 50 years and over living in the sampled households were considered eligible for the study. Sample size was defined as 10,000 persons (9,412 participated). For our investigation, we selected the participants who reported using one or more medications prescribed by a physician on a regular basis (n = 6,647). This and other data for this analysis were obtained with face-to-face interviews conducted at the household. More details on the ELSI-Brazil can be seen in another publication[@B14].

Variables and Data Collection
-----------------------------

The outcome variable was cost-related underuse of medications, measured by the question: "In the last 30 days, because of financial problems, did you: (a) stopped taking, (b) decreased the number of, (c) decreased the dose of (dividing the tablet or taking fewer doses) any medication prescribed by a physician?". We considered underuse the positive answer to any of the alternatives.

Exposure variables were selected based on the behavioral model of access and use of health services of Andersen[@B15]. This model lists the predisposing factors (sociodemographic characteristics), enabling factors (community and individual resources that favor or hinder access to services), and factors of need (health conditions) to explain the event. Although this theoretical framework was initially proposed to analyze the use of health services, the model has supported studies on the use of medications[@B2] ^,^ [@B7] ^,^ [@B10] ^,^ [@B13]. In this analysis, the predisposing factors included sex, age (50--59, 60--79, [@B3] 80 years), years of schooling (0, 1--10, 11 or more), marital status (married, single or separated, widow/widowed), and living arrangements (living alone or not). The enabling factors were region of residence, socioeconomic status of the household, sufficiency of the family income for expenses, health plan coverage, frequency with which the physician explains about the disease and the proposed treatment, and number of medications used. The socioeconomic position of the household was measured by a score created through principal component analysis[@B16], which considered the number of household appliances and number of vehicles, in addition to the presence of domestic workers. Factors of need were self-rated health and history of medical diagnosis of hypertension and diabetes.

Data Analysis
-------------

Initially, we examined the distribution of characteristics of the study participants according to the underuse of medications using Pearson's chi-square test with Rao-Scott correction. The analyses of the associations were based on prevalence ratios and 95% confidence intervals, which were estimated by univariate and multivariate Poisson regression, with robust variance. The multivariate models included those variables that showed associations with the outcome at p \< 0.20 level (Wald test) in the univariate analysis. The multivariate analysis started with the full model, followed by the selective deletion of variables according to the p value (backward), and successive models were compared by the likelihood-ratio test. The adequacy of the final model was evaluated by deviance statistics (p \> 0.05). Those variables that showed an association with the outcome at p \< 0.05 level were considered as independently associated with underuse of medication. Statistical analysis was conducted using the software Stata®, version 14.0, considering the sample weight of the individuals and the sample parameters (svy command).

The ELSI-Brazil was approved by the Research Ethics Committee of the *Instituto de Pesquisas René Rachou* of the *Fundação Oswaldo Cruz*, Minas Gerais (CAAE 34649814.3.0000.5091). All participants signed the informed consent.

RESULTS
=======

Of the 6,647 persons eligible for the study, 6,014 participated in this analysis. Exclusions were due to incomplete information of at least one of the variables considered. Excluded individuals did not differ from the participants in relation to sex and age (p \> 0.05). Among participants, mean age was 64.3 years (SD = 10.0) and females were predominant (59.2%).

The prevalence of underuse of medications in the last 30 days was 10.6% (95%CI 9.3-12.1) and it was higher among women (12.5%; 95%CI 10.7--14.6) than among men (7.9%; 95%CI 6.8--8.2). This prevalence decreased progressively with age, in both sexes ([Figure](#f01){ref-type="fig"}).

FigurePrevalence of cost-related underuse of medications according to age group, for total population, and stratified by sex. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015--2016.

[Table 1](#t1){ref-type="table"} shows the results of the univariate analyses of the associations between predisposing factors and underuse of medications. There were statistically significant associations (p \< 0.05) with the female sex, widowhood, and education level. No association was found with living alone (p = 0.084).

Table 1Distribution of predisposing variables according to cost-related underuse of medications. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015--2016. (n = 6,014)Predisposing variablesStudy population^a^Underuse of medications^b\ (%)^PR^c^95%CIp^d^Sex    \< 0.001Male2,2787.91.00  Female3,73612.51.581.31--1.91 Age (years)     50--592,13314.01.00 \< 0.00160--793,2848.90.640.53--0.77 80 and over5974.60.330.22--0.51 Education level (years)    0.012Zero94912.31.00  1--103,75611.40.930.74--1.16 11 or more1,3097.80.630.47--0.85 Marital status    0.014Married3,44310.61.00  Single/Separated1,27812.91.210.99--1.41 Widow/Widowed1,2938.20.780.61--0.99 Living alone    0.084No5,24110.81.00  Yes7738.80.810.63--1.06 [^3][^4][^5][^6]

All the enabling factors, except for geographical region (p = 0.278), showed statistically significant associations with underuse of medications ([Table 2](#t2){ref-type="table"}). They are: socioeconomic status of the household, sufficiency of income for expenses, private health plan coverage, explanation of the disease and treatment by the physician, and number of medical visits and medications used.

Table 2Distribution of enabling variables according to cost-related underuse of medications. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015--2016. (n = 6,014)Enabling variablesStudy population^a^Underuse of medications^b\ (%)^PR^c^95%CIp^d^Geographic region    0.278Southeast2,69710.21.00  Northeast1,50112.21.200.97--1.47 North35314.21.390.99--1.96 South8519.20.900.68--1.20 Midwest61210.41.020.75--1.39 Socioeconomic status (in quartiles)    \< 0.001Q11,55715.51.00  Q21,55011.10.720.57--0.90 Q31,50211.10.720.57--0.89 Q41,4055.50.360.27--0.48 Sufficiency of family income for expenses    \< 0.001Always2,0374.01.00  Sometimes1,5208.12.041.49--2.79 Never2,45718.24.593.57--5.90 Health insurance coverage    \< 0.001No4,38812.31.00  Yes1,6266.30.510.41--0.64 Physician explains about disease and treatment    \< 0.001Always4,9609.31.00  Rarely/Never1,05416.91.811.49--2.21 No. of medical appointments in the last 12 months    0.0190--11,3848.41.00  2--31,99210.81.291.00--1.66 4 or more2,63811.71.401.10--1.78 No. of medications used    \< 0.00111,5276.91.00  2--43,32811.41.651.30--2.09 5 or more1,15913.71.981.50--2.61 [^7][^8][^9][^10]

Self-rated health and history of medical diagnosis of depression showed statistically significant associations with underuse of medications. The history of medical diagnosis of hypertension and diabetes was not found to be associated with the outcome \[p = 0.293 and p = 0.623, respectively ([Table 3](#t3){ref-type="table"})\].

Table 3Distribution of the variables of health needs according to cost-related underuse of medications. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015--2016. (n = 6,014)Predisposing variablesStudy population^b^Underuse of medications^c\ (%)^PR^d^95%CIp^e^Self-rated health    \< 0.001Very good/Good2,2994.31.00  Fair2,90511.92.752.16--3.53 Poor/Very poor81024.95.764.44--7.47 Hypertension^a^     No1,88011.71.00  Yes4,13410.60.920.77--1.110.293Diabetes^a^     No4,71810.51.00  Yes1,29611.11.050.86--1.300.623Depression^a^    \< 0.001No4,6857.91.00  Yes1,32919.92.512.11--2.98 [^11][^12][^13][^14][^15]

The final results of the multivariate analysis of the factors associated with underuse of medications are presented in [Table 4](#t4){ref-type="table"}. Among those predisposing factors, independent and statistically significant associations (p \< 0.05) were found for female sex (PR = 1.39) and age (PR = 0.75 and 0.43 for the age group of 60--79 and 80 years and over, respectively, compared to younger persons). Regarding enabling factors, the socioeconomic status of the household (RP = 0.70, 0.79, and 0.60 for the second, third, and fourth quartiles (in relation to the first one), respectively) and private health insurance coverage (PR = 0.79) showed negative associations. Positive associations were found for sufficiency of family income for expenses (RP = 1.74 and 2.94 for sometimes and never, respectively, compared to always), frequency with which the physician explains about the disease and treatment (PR = 1, 31 for rarely or never), and number of medications used (PR = 1.39 for 2--4 and 1.53 for 5 or more). Among factors of need, poorer self-rated health (PR = 2.02 and 2.92 for fair and poor or very poor, respectively) and history of medical diagnosis of depression (PR = 1.69) showed positive associations.

Table 4Final results of the multivariate analysis of the characteristics associated with cost-related underuse of medications. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015--2016.VariableAdjusted PR^a^95%CISex (ref: male)  Female1.391.16--1.67^b^Age (ref: 50--59 years)  60--790.750.63--0.89^c^80 and over0.430.28--0.67^b^Socioeconomic status in quartiles (ref: Q1)  Q20.700.57--0.87^c^Q30.790.64--0.97^c^Q40.600.44--0.77^b^Sufficiency of monthly family income for expenses (ref: always)  Sometimes1.741.28--2.35^b^Never2.942.29--3.79^b^Health insurance coverage (ref: no)  Yes0.790.63--0.98^c^Frequency with which the physician explains about the disease and treatment (ref: frequently)Rarely/Never1.311.09--1.57^c^Number of medications used (ref: 1)  2--41.391.11--1.74^c^5 or more1.531.16--2.02^c^Self-rated health (ref: very good/good)  Fair2.021.60--2.57^b^Poor/Very poor2.922.23--3.81^b^Depression (ref: no)  Yes1.691.41--2.02^b^[^16][^17][^18]

DISCUSSION
==========

The main results of this analysis were: (1) approximately one in 10 study participants reported cost-related underuse of medications; (2) age, sex, and poor socioeconomic status (assessed by the score of household goods and perceived sufficiency of income) were important factors associated with underuse of medications; (3) the source of care (private health plan coverage), the quality of care (frequency with which the physician explains about the disease and treatment), and the number of medications used were also associated with the outcome; (4) persons with poorer self-rated health and with depression were more likely to have a cost-related underuse of medications. On the other hand, there were no associations between hypertension and diabetes and underuse of medications.

The frequency with which participants had a cost-related underuse of medications (10.6%) was similar to that observed among Canadian adults aged 18 years and over (9.9%)[@B10] and higher than that observed in the United States, in the same age group (5.1%)[@B7]. In the age group of 60 years and over, the cost-related underuse of medications observed in this analysis (8.3%; data not shown) was higher in relation to European older adults (3.6%)[@B6] but lower than that observed in the metropolitan area of Belo Horizonte, Brazil, (12.9%)[@B13] and in the United States (20%)[@B9]. In addition to methodological issues related to how the outcome was defined, specificities of local policies for pharmaceutical care and coverage of the costs of medications may explain the above mentioned differences in prevalence.

Regarding predisposing factors, the prevalence of underuse of medications was higher among women and lower in older ages, regardless of the enabling factors and factors of need. Women complain more intensely and frequently of health problems and use more medications than men, which result in higher costs with pharmacotherapy[@B1] ^,^ [@B2]. Higher spending with medications increases the financial pressure of women, who are more vulnerable than men in terms of income, socioeconomic status, and education level[@B6] ^,^ [@B9]. As for age, our results are in line with what has been reported in other populations^4,8--10^, showing that the cost-related underuse of medications decreases with age. With aging, health concern and vigilance increases, and non-adherence to treatment is perceived as harmful[@B17].

The enabling variables are those that are more subject to modifications from public policies and the way health services are organized[@B15]. The financing of the costs with medications (partial or total subsidy to the prescribed medication, linked to specific care programs) can alleviate the financial pressures that hinder access[@B18] ^,^ [@B19]. The quality of the medical consultation (prescriptions that promote the rational use of medications, provision of explanations, and guidance to the patient), as well as pharmaceutical care services, can reduce the risks of non-adherence to the prescribed medication[@B20]. Income and socioeconomic status are the enabling factors most directly related to cost-related underuse, since they enable the individual to acquire medications. Our results are in line with other investigations that show consistent associations between higher income and lower underuse of medications[@B4] ^,^ [@B7] ^,^ [@B8] ^,^ [@B10] ^,^ [@B13].

As with European older adults[@B6], Brazilian older adults who perceive their family income as insufficient for expenses underuse more medications, regardless of other relevant factors including the score of household goods. Perceived sufficiency of household income for expenses is an important indicator of financial difficulties. Individuals with a similar income, but with a perception that their income is insufficient for expenses, usually react differently to the cost pressures involved in drug treatment, thus reducing the use in the face of a small increase in cost or adhering completely to the prescription, given the significant increase in the costs of medications[@B2] ^,^ [@B11]. Possibly other issues are considered in this process, such as the perception of the health risks involved or the value given to the medication in the treatment of the disease[@B17]. Our results support the hypothesis that expenses with medications can be disregarded when financial difficulties compel the individual to prioritize family expenses[@B2] [@B1].

Individuals covered by private health plan tend to present fewer financial barriers to the use of health services, as these barriers act by increasing social inequalities in access to these services. This could explain the lower underuse of medications observed among participants with health plan coverage, which is consistent with results found in other countries[@B4] ^,^ [@B7] ^,^ [@B8] ^,^ [@B10] and in a Brazilian metropolitan region[@B13].

The results regarding the greater underuse of medications among those with poorer socioeconomic status and those not covered by health plan reinforce the importance of governmental initiatives that seek to improve access to medications. The Brazilian Unified Health System (SUS) includes pharmaceutical care as a component of comprehensive health care, and the Brazilian Popular Pharmacy Program [@B22] is an important initiative to ensure this right to the citizen. This program can contribute with better adherence to pharmacological treatment among persons with lower socioeconomic level, especially those who live in places where public pharmaceutical care is not sufficiently organized. Recent studies have shown that, among Brazilians, a little more than a third of persons with hypertension and more than half of the persons with diabetes obtained at least one of the medications used to control their respective diseases in the Brazilian Popular Pharmacy Program [@B23], and approximately 72% of the medications used in the treatment of hypertension were obtained from the SUS and 16% was provided by this program [@B24]. Our results showed no association of hypertension and diabetes with cost-related underuse of medications, in contrast to that observed for self-rated health and depression. This lack of association can be explained by the policies mentioned above.

As observed among Brazilian older adults (≥ 60 years)[@B13] and among adults (≥ 18 years) from higher income countries[@B8], our study identified a greater underuse of medications among those who did not feel well informed by the physician about their disease and treatment. Patients are more willing to overcome difficulties in acquiring medications when they are heard about their values and concerns (including financial ones) and when they have answers about the disease and its treatment[@B5] ^,^ [@B8]. The judgment of patients regarding accessibility to medication can vary and it may be difficult for the health professional to distinguish between inability to afford and unwillingness to purchase the medication needed for treatment[@B10]. Health professionals should be aware that the quality of information, including answering the patients' questions, can increase adherence and, consequently, intensify the effectiveness of treatment.

In our study, the number of medications used was associated with cost-related underuse. In addition to financial pressures, the amount of prescribed medications is considered as the main determinant of underuse, followed by individual characteristics (perceptions of the risks or benefits of the treatment) and the medication itself (possible side effect, complex administration)[@B18] ^,^ [@B21]. Health professionals can contribute minimizing underuse in these conditions when associating the quality of the prescription at an affordable cost. To this end, they can prescribe cheaper medications or increase the time needed for a prescription renewal, as well as give advice about the possibility of obtaining the medication in public pharmacies or in programs that provide subsidized medication.

Among the factors of need, poorer self-rated health and a previous medical diagnosis of depression were independently and positively associated with underuse of medications. The results related to self-rated health corroborate that observed in other populations[@B7] ^,^ [@B8] ^,^ [@B10] ^,^ [@B13]. Positive associations between cost-related underuse of medications and depression have been shown in another study[@B8]. In the United States, among those with chronic diseases, depression was associated with underuse of prescribed medications and those specific for the treatment of depression. Persons with depression may have impaired cognitive function and lower levels of energy and motivation, which may affect their willingness to spend on medications[@B8]. It is possible that the judgment of patients on the role of the medication in preventing the progression of the disease or the perception of a transitory nature of the depression may favor underuse among depressed individuals. Positive associations between poor health status and cost-related underuse of medication are worrying. Persons with poorer health conditions are at greater risk for the clinical consequences of non-adherence to the proposed therapeutic regimen[@B10], as these consequences are minimized or ignored.

This study presents some limitations that hinder a more in-depth interpretation of its results. These limits refer to the impossibility of identifying the underused medication, which could indicate more clearly whether underuse is selective. Selectivity may reflect perceptions about the value of the proposed treatment and the importance of including the medication in the treatment. Aspects related to the provision and organization of health services, especially in relation to pharmaceutical care, can also contribute to this selectivity. On the other hand, the strength of the study arises from its comprehensiveness and the representativeness of the sample, which gives it originality. This is the first study to investigate cost-related underuse of medications which allows inference of its results to the Brazilian adult population aged 50 years and over.

In summary, our results point to the multidimensional and complex nature of the cost-related underuse of medications. Given the importance assumed by the medication in the treatment of different diseases, the costs they represent to patients, and the health risks of not adhering to the proposed pharmacotherapy, health professionals should strive to make treatment feasible. In this sense, the discussion with the patient about the disease and its treatment, the adequacy of the prescription to the patient's ability to pay, and the provision of information that helps to overcome barriers to available medications should be offered. Regarding health planners, actions that enhance the universalization of pharmaceutical care, such as regular availability of medications in pharmacies of the SUS and the Brazilian Popular Pharmacy Program, can certainly contribute to reduce the underuse of medications and promote equality and equity in the access to them with positive impacts on the health of the population.
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[^3]: ^a^ Unweighted.

[^4]: ^b^ Weighted by sampling design

[^5]: ^c^ PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.

[^6]: ^d^ Pearson's chi-square test, for comparison of proportions, with Rao-Scott correction.

[^7]: ^a^ Unweighted by sample weight.

[^8]: ^b^ Weighted by sample weight.

[^9]: ^c^ PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.

[^10]: ^d^ Pearson's chi-square test with Rao-Scott correction.

[^11]: ^a^ Previous medical diagnosis

[^12]: ^b^ Unweighted.

[^13]: ^c^ Weighted by sampling design .

[^14]: ^d^ PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.

[^15]: ^e^ Pearson's chi-square test with Rao-Scott correction.

[^16]: ^a^ Adjusted PR (95%CI): prevalence ratio estimated by Poisson regression model with robust variance, adjusted for all variables described in the table.

[^17]: ^b^ p \< 0.001

[^18]: ^c^ p \< 0.05
